Barclays PLC Has $1.60 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Barclays PLC raised its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 15.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 266,066 shares of the company's stock after acquiring an additional 35,889 shares during the period. Barclays PLC owned approximately 0.18% of Adaptive Biotechnologies worth $1,596,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ADPT. KBC Group NV acquired a new stake in Adaptive Biotechnologies in the 4th quarter worth $50,000. GAMMA Investing LLC bought a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $59,000. Cibc World Markets Corp acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at $65,000. Proficio Capital Partners LLC bought a new stake in Adaptive Biotechnologies during the fourth quarter worth about $93,000. Finally, Amundi grew its holdings in shares of Adaptive Biotechnologies by 41.2% during the fourth quarter. Amundi now owns 15,532 shares of the company's stock worth $93,000 after purchasing an additional 4,531 shares during the last quarter. Institutional investors own 99.17% of the company's stock.

Insiders Place Their Bets

In related news, Director Peter M. Neupert sold 10,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.05, for a total value of $70,500.00. Following the completion of the transaction, the director now owns 224,690 shares of the company's stock, valued at $1,584,064.50. The trade was a 4.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Chad M. Robins sold 211,160 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the sale, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,901,958.50. This represents a 7.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 826,013 shares of company stock worth $6,543,452 in the last quarter. 6.20% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Stock Performance

ADPT traded up $0.17 during trading hours on Thursday, reaching $8.98. The company's stock had a trading volume of 269,951 shares, compared to its average volume of 2,147,969. Adaptive Biotechnologies Co. has a 52 week low of $2.99 and a 52 week high of $10.28. The firm has a market cap of $1.36 billion, a PE ratio of -8.24 and a beta of 1.75. The company's 50-day moving average is $7.82 and its 200-day moving average is $6.98.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.08. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. The company had revenue of $52.44 million for the quarter, compared to the consensus estimate of $42.13 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share. The firm's revenue for the quarter was up 25.2% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. The Goldman Sachs Group lifted their price objective on Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Scotiabank boosted their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 13th. Morgan Stanley upped their price target on Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Monday. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $13.00 target price (up previously from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus target price of $9.83.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.